Travis Steed
Stock Analyst at B of A Securities
(2.76)
# 2,777
Out of 5,165 analysts
92
Total ratings
45.07%
Success rate
6.08%
Average return
Main Sectors:
Stocks Rated by Travis Steed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Upgrades: Neutral | $15 → $30 | $23.91 | +25.47% | 3 | Feb 20, 2026 | |
| BBNX Beta Bionics | Maintains: Buy | $30 → $33 | $10.64 | +210.15% | 1 | Jan 5, 2026 | |
| PEN Penumbra | Maintains: Buy | $320 → $370 | $338.00 | +9.47% | 2 | Jan 5, 2026 | |
| BDX Becton, Dickinson and Company | Maintains: Neutral | $190 → $207 | $161.64 | +28.06% | 10 | Jan 5, 2026 | |
| CNMD CONMED | Maintains: Neutral | $65 → $52 | $37.34 | +39.26% | 5 | Dec 8, 2025 | |
| MASI Masimo | Initiates: Neutral | $162 | $175.97 | -7.94% | 1 | Nov 17, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $133 → $150 | $110.71 | +35.49% | 5 | Mar 10, 2025 | |
| SOLV Solventum | Maintains: Neutral | $80 → $85 | $68.67 | +23.78% | 3 | Feb 26, 2025 | |
| EW Edwards Lifesciences | Upgrades: Buy | $82 → $90 | $84.27 | +6.80% | 4 | Dec 16, 2024 | |
| CBLL CeriBell | Initiates: Buy | $32 | $19.50 | +64.10% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $42 → $45 | $17.62 | +155.39% | 5 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $480 → $45 | $3.61 | +1,146.54% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $315 | $349.11 | -9.77% | 5 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $365 → $295 | $230.49 | +27.99% | 3 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $32.75 | -51.15% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 → $160 | $92.52 | +72.94% | 11 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $315 | $482.76 | -34.75% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $8 | $1.62 | +393.83% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $25 | $8.91 | +180.58% | 1 | Jun 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $85 | $13.65 | +522.71% | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $67.32 | +85.68% | 7 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $145 | $88.44 | +63.95% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $51 | $71.20 | -28.37% | 9 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $59 → $54 | $9.10 | +493.41% | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $80.45 | -72.65% | 1 | Jul 17, 2017 |
Tandem Diabetes Care
Feb 20, 2026
Upgrades: Neutral
Price Target: $15 → $30
Current: $23.91
Upside: +25.47%
Beta Bionics
Jan 5, 2026
Maintains: Buy
Price Target: $30 → $33
Current: $10.64
Upside: +210.15%
Penumbra
Jan 5, 2026
Maintains: Buy
Price Target: $320 → $370
Current: $338.00
Upside: +9.47%
Becton, Dickinson and Company
Jan 5, 2026
Maintains: Neutral
Price Target: $190 → $207
Current: $161.64
Upside: +28.06%
CONMED
Dec 8, 2025
Maintains: Neutral
Price Target: $65 → $52
Current: $37.34
Upside: +39.26%
Masimo
Nov 17, 2025
Initiates: Neutral
Price Target: $162
Current: $175.97
Upside: -7.94%
Abbott Laboratories
Mar 10, 2025
Maintains: Buy
Price Target: $133 → $150
Current: $110.71
Upside: +35.49%
Solventum
Feb 26, 2025
Maintains: Neutral
Price Target: $80 → $85
Current: $68.67
Upside: +23.78%
Edwards Lifesciences
Dec 16, 2024
Upgrades: Buy
Price Target: $82 → $90
Current: $84.27
Upside: +6.80%
CeriBell
Nov 5, 2024
Initiates: Buy
Price Target: $32
Current: $19.50
Upside: +64.10%
Mar 5, 2024
Maintains: Neutral
Price Target: $42 → $45
Current: $17.62
Upside: +155.39%
Oct 13, 2023
Downgrades: Underperform
Price Target: $480 → $45
Current: $3.61
Upside: +1,146.54%
Sep 5, 2023
Upgrades: Buy
Price Target: $315
Current: $349.11
Upside: -9.77%
Aug 24, 2023
Maintains: Buy
Price Target: $365 → $295
Current: $230.49
Upside: +27.99%
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $32.75
Upside: -51.15%
May 3, 2023
Upgrades: Neutral
Price Target: $120 → $160
Current: $92.52
Upside: +72.94%
Apr 19, 2023
Maintains: Buy
Price Target: $300 → $315
Current: $482.76
Upside: -34.75%
Jan 3, 2023
Downgrades: Underperform
Price Target: $8
Current: $1.62
Upside: +393.83%
Jun 21, 2022
Initiates: Underperform
Price Target: $25
Current: $8.91
Upside: +180.58%
Oct 13, 2021
Maintains: Overweight
Price Target: $120 → $85
Current: $13.65
Upside: +522.71%
May 25, 2021
Initiates: Overweight
Price Target: $125
Current: $67.32
Upside: +85.68%
May 25, 2021
Initiates: Equal-Weight
Price Target: $145
Current: $88.44
Upside: +63.95%
May 25, 2021
Initiates: Overweight
Price Target: $51
Current: $71.20
Upside: -28.37%
Nov 1, 2018
Maintains: Neutral
Price Target: $59 → $54
Current: $9.10
Upside: +493.41%
Jul 17, 2017
Initiates: Overweight
Price Target: $22
Current: $80.45
Upside: -72.65%